PLX8394 is primarily used in research and clinical settings to target specific genetic mutations, particularly in cancer therapy. It functions as an inhibitor of BRAF mutations, which are commonly found in melanoma and other cancers. By blocking the activity of mutated BRAF proteins, it helps to slow down or stop the growth of cancer cells. This makes it a promising candidate for personalized medicine, especially in patients who do not respond to traditional treatments. Additionally, PLX8394 is being studied for its potential to overcome resistance mechanisms that develop in response to other BRAF inhibitors, offering hope for more effective long-term cancer management. Its application extends to preclinical studies, where it aids in understanding the molecular pathways involved in cancer progression and drug resistance.